Racetams & AMPAkines — References

Mirrored Reference Dossier

Parent Topic: Racetams & AMPAkines | References Hub: 02 - Compounds & Molecules References MOC

Landmark Peer-Reviewed Studies

Citation: Waegemans, T., Wilsher, C. R., Danniau, A., Ferris, S. H., Kurz, A., & Winblad, B. (2002). Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dementia and Geriatric Cognitive Disorders, 13(4), 217–224.
Identifiers: PMID: 12006732 (PubMed · Europe PMC) | DOI: 10.1159/000057700 (DOI · SciDB · Scholar)
Study Design & Sample Size: Systematic meta-analysis of 19 randomized, double-blind, placebo-controlled parallel-group trials evaluating piracetam ( $2.4 - 8.0 g/day$ over 6–52 weeks) in older adults with cognitive impairment ( $N = 1, 488$ ).
**Key Quantitative Outcomes:**60.9% of patients treated with piracetam demonstrated clinical global impression of change (CGIC) improvement compared to 32.8% on placebo, yielding a Mantel-Haenszel Odds Ratio of $3.35$ ( $95% CI: 2.70 - 4.17, p < 0.001$ ) and a Number Needed to Treat ( $NNT$ ) of $3.6$ .

Citation: Malykh, A. G., & Sadaie, M. R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312.
Identifiers: PMID: 20166767 (PubMed · Europe PMC) | DOI: 10.2165/11319230-000000000-00000 (DOI · SciDB · Scholar)
Study Design & Sample Size: Comprehensive pharmacological review of Structure-Activity Relationships (SAR), membrane biophysics, AMPA receptor modulation, and clinical trials across Piracetam, Oxiracetam, Aniracetam, Phenylpiracetam, and Levetiracetam.
Key Quantitative Outcomes: Detailed how piracetam binds phospholipid polar headgroups in a dose-dependent manner ( $100 μ M - 1 mM$ ) to decrease membrane anisotropy (restoring fluidity by $+ 15 - 25%$ in aged synaptosomes), allosterically increases AMPA receptor $B_{m a x}$ density, enhances erythrocyte deformability, and increases prostacyclin ( $PGI_{2}$ ) synthesis while inhibiting thromboxane $A_{2}$ ( $TXA_{2}$ ) by $- 30 - 40%$ .

Citation: Ostrovskaya, R. U., Gudasheva, T. A., Zaplina, A. P., Vahitova, J. V., Salimgareeva, M. H., Jamidanov, R. S., & Seredenin, S. B. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of Experimental Biology and Medicine, 146(3), 334–337.
Identifiers: PMID: 19240853 (PubMed · Europe PMC) | DOI: 10.1007/s10517-008-0297-x (DOI · SciDB · Scholar)
Study Design & Sample Size: Preclinical Northern blot mRNA gene expression study in male Wistar rats comparing acute and chronic ( $28 -day$ ) administration of Noopept ( $0.5 mg/kg$ i.p.).
Key Quantitative Outcomes: Chronic administration of Noopept increased hippocampal Nerve Growth Factor (NGF) mRNA expression by $+ 65%$ and Brain-Derived Neurotrophic Factor (BDNF) mRNA expression by $+ 48%$ ( $p < 0.01$ ), without inducing tolerance or neurotrophin exhaustion in the cerebral cortex.

Citation: Neznamov, G. G., & Teleshova, E. S. (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neuroscience and Behavioral Physiology, 39(3), 311–321.
Identifiers: PMID: 19234797 (PubMed · Europe PMC) | DOI: 10.1007/s11055-009-9128-4 (DOI · SciDB · Scholar)
Study Design & Sample Size: 56-day randomized comparative clinical trial ( $N = 53$ ) comparing Noopept ( $20 mg/day$ ) vs. Piracetam ( $1, 200 mg/day$ ) in patients with post-concussive or cerebrovascular mild cognitive impairment.
Key Quantitative Outcomes: Both agents significantly improved MMSE, BPRS, and CCSE cognitive scores ( $p < 0.01$ ), but Noopept acted at a $60 \times$ lower daily milligram dose, produced a broader anxiolytic/anti-asthenic effect starting by week 2, and resulted in $1.8 \times$ fewer adverse events ( $18.2%$ vs. $32.0%$ psychomotor agitation/sleep disturbance with piracetam).